1. A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound.
A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. Twelve days after intrapancreatic injection of KP4 cells, nude (nu/nu) mice received ultrasound imaging and were then treated with vehicle or MetMAb (30 mg/kg, i.p., twice weekly) for 2 wk. Ultrasound imaging was repeated 2 wk after treatment initiation. Treatment was continued for 11 wk, and survival was followed for 90 d after cell injection. Animal number was 19 to 20 in each group. There was no difference in tumor volume measured by ultrasound before treatment (8.34 ± 3.51 mm3 and 8.63 ± 3.61 mm3 in vehicle- and MetMAb-treated mice, respectively). A, tumor volume measured by ultrasound 2 wk after treatment initiation. B, fold change in tumor volume measured by ultrasound. ***, P < 0.001, between groups. C, effect of 11-wk treatment with MetMAb on survival. Log-rank (Mantel-Cox) comparison of survival plots indicated P = between the two group. D, effect of 2-wk treatment with MetMAb on survival in the orthotopic model of pancreatic cancer. Twelve days after intrapancreatic injection of KP4 tumor cells, nude (nu/nu) mice were treated with vehicle or MetMAb (30 mg/kg, i.p., twice weekly) for 2 wk, and survival was followed for 90 d after cell injection. Log-rank (Mantel-Cox) comparison of survival plots indicated P = between treatment groups.
Hongkui Jin et al. Cancer Res 2008;68:
©2008 by American Association for Cancer Research